A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis

Authors
Category Primary study
Registry of TrialsANZCTR
Year 2005
INTERVENTION: A 6‐month randomised double‐blind trial of 250mg daily versus 1200mg weekly azithromycin in cystic fibrosis CONDITION: Cystic Fibrosis PRIMARY OUTCOME: Change in FEV1 % predicted. SECONDARY OUTCOME: Hospital days Antibiotic use BMI, CRP levels Cytokine response and bacteriology QOL INCLUSION CRITERIA: Consenting children and adults (age >/6 years; weight >/ 25kg) with Clinically stable (at least 2 weeks since last acute IV/oral antibiotic therapy; FEV1 within 10% of average for last 6 months).
Epistemonikos ID: d8a44d82db466f2bbcbcb795c6c70d3009a6ab04
First added on: Aug 21, 2024